Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIPERT-CIDP Phase 3 Trial of Ripertamab in CIDP
ChiCTR2600120227Phase 3Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Ripertamab treatment group with Placebo control group (2 arms). Primary endpoint: Risk of recurrence. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on ChiCTR2600120227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120227.